The average annual growth rate in net prices for multiple sclerosis drugs ranged from 10.2 percent to 15 percent between 2011 and 2015, a new report says.
Drug makers may offer rebates to payers, but health plans continue to see notable increases in costs for prescription medicines, according to a report by the office of Massachusetts Attorney General Maura Healey. And this has been especially true for one particularly costly group of medicines used to treat multiple sclerosis.
In 2015, the average spending per member each month for all medicines rose 6.1 percent from 2014, after rebates, among five state health plans that were examined. And average spending increased 21.4 percent from 2014, after rebates, for five different types of specialty drugs for treating cancer, hepatitis C, HIV, rheumatoid arthritis, and multiple sclerosis.
